Article
A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.
BMC cancer - 31 Jul 2021
Yu Wanjun, Ye Fei, Yuan Xiao, Ma Yali, Mao Chaoming, Li Xiaoqin, Li Jian, Dai Chunhua, Qian Fenhong, Li Junrong, Fan Xiujuan, Zhou Yuepeng, Wang Deqiang, Guo Zhenhong, An Huazhang, Zhang Minghui, Chen Deyu, Xia Sheng
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, have achieved good efficacy in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients, but eventual drug resistance is inevitable. Thus, new TKI-based combination therapies should be urgently explored to extend the overall survival time of these patients. CD8 + CD56+ natural killer T (NKT) cells are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.